Navigation Links
Department of Defense Exercises Options Under Contract for Nerve Agent Medical Countermeasure Program
Date:8/9/2012

te forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Form 10-K under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, significant additional research work, non-clinical animal studies, human clinical trials, and manufacturing development work remain to be done with respect to rBChE. At this point there can be no assurance that this product candidate will be shown to be safe and effective and approved by regulatory authorities for use in humans. Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at http://www.ph
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Hong Kong Department of Health to Combat Sudden Cardiac Arrest With Powerheart AEDs
2. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
3. Luminex Corporation to Speak at Joint Department of Defense and Environmental Protection Agency 5th National Bio-Threat Conference
4. CEM President and CEO Delivers Commencement Address at the 2012 University of Texas at Austin Chemistry and Biochemistry Department Graduation
5. Covenant Security Services and the Department of Homeland Security Partner to Provide Nationwide Training on Active Shooter Awareness and Response
6. InVigor® Canola Supports the Michigan-Whitman Fire Department with More for Everyone Award
7. Merck Company Foundation Announces HIV Care Collaborative with Atlanta, Houston and Philadelphia Health Departments
8. JoVE partners with US government to publish cutting-edge defense research
9. National Defense Industrial Association (NDIA) Opens Registration For 2012 Biosurveillance Conference, Set For August 27-28 in Washington, D.C.
10. Soligenix Announces Collaboration with Infectious Disease Research Institute to Develop Thermostabilized Biodefense Vaccines Utilizing Novel Adjuvants
11. National Defense Industrial Association's (NDIA) 2012 Biosurveillance Conference To Feature Keynote Speaker Laurie Garrett, Pulitzer Prize Winner and Bestselling Author
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DIEGO, Aug. 29, 2014  Pfenex Inc. (NYSE ... the development of high-value and difficult to manufacture ... update and reported financial results for the second ... the successful completion of our initial public offering, ... our biosimilar product candidates, derived from our proprietary ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Pittcon is ... MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, have organized ... September 5, 2014. JASIS , Asia’s largest analytical ... 2014, in Makuhari Messe, Japan. , The four ... for Bioanalysis from Single Molecules to Single Cells” will ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Due to a ... last week, the Adult Stem Cell Technology Center, LLC ( ... support stem cell therapy research that might benefit ALS patients. ... cells for new stem cell technologies and therapeutic applications, FRC ... Ice Bucket Challenge donors who wish not to support ...
(Date:8/28/2014)... Best Sanitizers, Inc., a leader in hand ... is asking industry professionals to prepare for fall harvest ... soap they’re currently using to the Best Sanitizers’ ... hygiene is critical to fighting cross-contamination and the spread ... criteria are identified to evaluate the effectiveness of an ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2
... paper,published today, scientists at deCODE genetics (Nasdaq: ... a novel insight into the connection,between inflammation and ... Icelanders, the deCODE team discovered several common single-letter,variations ... that increase levels of,eosinophils in the bloodstream. These ...
... Feb. 9 Aerovance Inc. today announced the appointment ... senior vice president and chief medical officer.Dr. Otulana, 52, ... leadership to the company as it moves forward with ... for severe atopic eczema. He has more than 20 ...
... plc (LSE: SHP, NASDAQ: SHPGY ), the global specialty ... 2009. , , Results press release will be ... Investor meeting and conference call time: 14:00 GMT ... meeting and conference call: , Angus Russell, ...
Cached Biology Technology:Multinational deCODE Study Identifies New Link Between Inflammation and Heart Attack 2Multinational deCODE Study Identifies New Link Between Inflammation and Heart Attack 3Multinational deCODE Study Identifies New Link Between Inflammation and Heart Attack 4Aerovance Appoints Babatunde A. Otulana, M.D., as Chief Medical Officer 2Full Year 2008 Results Date Notification - 19 February 2008 2
(Date:9/1/2014)... Mass-- Conventional wisdom has long held that corals ... coral reefs are passive organisms that rely ... such as nutrients and oxygen. But now scientists ... (WIS) in Israel have found that they are ... water into turbulent patterns that greatly enhance their ...
(Date:9/1/2014)... As nocturnal animals, bats are perfectly adapted to a life ... between the reflected echoes to measure distance to obstacles or ... different echo delays. A study carried out by researchers at ... that this map dynamically adapts to external factors. , ... bat flies in too close to an object, the number ...
(Date:8/31/2014)... of the greatest challenges in modern medicine is developing ... with minimal toxicity and side-effects to the patient. Such ... the drug molecule. Ideally, the drug should have a ... so that it binds it with high specificity. Publishing ... a synthetic amino acid that can impact the 3D ...
Breaking Biology News(10 mins):Nature's tiny engineers 2Nature's tiny engineers 3Zooming in for a safe flight 2A new synthetic amino acid for an emerging class of drugs 2A new synthetic amino acid for an emerging class of drugs 3
... A man,s height is a modest marker for ... linked to progression of the cancer, say British researchers ... also reviewed 58 published studies. In the September ... a journal of the American Association for Cancer Research, ...
... widely cultivated crop that has been subjected to intensive ... years ago). The domestication of grapevine has undergone a ... The recent publication of the complete grapevine genome ... its content. This sequencing has shown that genes constitute ...
... discovered that a gene controlling whether blood vessels differentiate ... to a vascular disorder in the brain that causes ... and the new findings are the first to provide ... particular brain disorder, known as BAVM, and to provide ...
Cached Biology News:Height linked to risk of prostate cancer development and progression 2Gene is likely cause of stroke-inducing vascular malformations 2Gene is likely cause of stroke-inducing vascular malformations 3
Blimp-1 (H-150)...
... /K + ATPase α-1, clone C464.6 ... Immunogen : Purified Na + /K + ... rabbit kidney outer medulla Formulation: 0.1M Tris-glycine, ... azide Quality Assurance: routinely evaluated in immunoblot ...
Immunogen: Purified native p24 from strain IIIB. Storage: -20 C, Avoid Freeze/Thaw Cycles...
EDG-1CT (endothelial cell differentiation gene-1, C terminal)...
Biology Products: